Clovis Oncology Inc. (CLVS) announced Monday morning that its Phase 3 trial of rucaparib successfully achieved the primary endpoint of improved progression-free survival in patients with ovarian cancer.
from RTT - Hot Stocks http://ift.tt/2sH66eR
via IFTTT
No comments:
Post a Comment